Work

448P Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in the first line (1L) setting among patients with metastatic triple-negative breast cancer (mTNBC)

Year: 2026

Type: article

Abstract: OS is often considered the gold standard in oncology trials for evaluating treatment efficacy. However, treatment crossovers (as part of study design or standard of care [SOC]) can confound OS interpretation. Predicting OS from a surrogate end point not affected by crossovers (eg, PFS) is of interest. We evaluated if PFS can be a surrogate for OS in 1L treatment of mTNBC (overall and by programmed death ligand 1 [PD-L1] status).

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.107471